Published in Genes Dev on September 15, 2001
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
DNA polymerase eta is targeted by Mdm2 for polyubiquitination and proteasomal degradation in response to ultraviolet irradiation. DNA Repair (Amst) (2011) 1.58
Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J (2003) 1.48
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet (2008) 1.43
Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol (2003) 1.42
Tumor suppressor protein (p)53, is a regulator of NF-kappaB repression by the glucocorticoid receptor. Proc Natl Acad Sci U S A (2011) 1.14
The p53 tumour suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO Rep (2002) 1.07
Molecular characterization of SMILE as a novel corepressor of nuclear receptors. Nucleic Acids Res (2009) 1.07
Hypoxia-induced assembly of prolyl hydroxylase PHD3 into complexes: implications for its activity and susceptibility for degradation by the E3 ligase Siah2. Biochem J (2007) 1.01
Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer (2004) 0.93
Nuclear receptors in inflammation control: repression by GR and beyond. Mol Cell Endocrinol (2013) 0.90
Lysine 419 targets human glucocorticoid receptor for proteasomal degradation. Steroids (2010) 0.90
Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells. PLoS One (2012) 0.90
The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling. Mol Cell Biol (2004) 0.85
Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. PLoS One (2013) 0.82
P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer (2006) 0.82
Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε. J Biol Chem (2012) 0.81
In vivo radioadaptive response: a review of studies relevant to radiation-induced cancer risk. Hum Exp Toxicol (2014) 0.79
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. J Mol Endocrinol (2015) 0.79
Dexamethasone in the presence of desipramine enhances MAPK/ERK1/2 signaling possibly via its interference with β-arrestin. J Neural Transm (Vienna) (2013) 0.78
Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53 K317R knock-in mouse thymocytes. Mol Cell Proteomics (2008) 0.78
Alteration of 11β-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor by ethanol in rat liver and mouse hepatoma cells. J Diabetes Res (2013) 0.77
The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases. Microbiol Mol Biol Rev (2016) 0.76
Small-molecule hormones: molecular mechanisms of action. Int J Endocrinol (2013) 0.75
The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis. Am J Blood Res (2014) 0.75
Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Biochemistry (2010) 0.75
Roles of alternative splicing in modulating transcriptional regulation. BMC Syst Biol (2017) 0.75
Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial. Clin Cancer Res (2017) 0.75
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell (1994) 8.65
Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev (1997) 8.51
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res (1993) 6.31
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J (1999) 4.68
The ARF/p53 pathway. Curr Opin Genet Dev (2000) 4.13
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature (1998) 4.03
Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene (1993) 3.43
The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol (2000) 3.25
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
Regulation of p53 in response to DNA damage. Oncogene (1999) 3.23
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol (2000) 3.07
Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J (1985) 2.98
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene (2000) 2.84
Distinct TFIID complexes mediate the effect of different transcriptional activators. EMBO J (1993) 2.66
MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol (2000) 2.50
The cellular response to p53: the decision between life and death. Oncogene (1999) 2.31
Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol (2001) 2.19
Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol (1990) 2.12
Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol (1996) 1.98
The glucocorticoid receptor is required for stress erythropoiesis. Genes Dev (1999) 1.92
Immunohistochemical localization of phosphoenolpyruvate carboxykinase in adult and developing mouse tissues. J Histochem Cytochem (1990) 1.84
Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem (1997) 1.83
Hdmx stabilizes Mdm2 and p53. J Biol Chem (2000) 1.81
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68
Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol (1996) 1.61
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol (2000) 1.54
The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol (1998) 1.53
p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene (1999) 1.47
Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol (2000) 1.47
The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem (1997) 1.44
Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med (1989) 1.38
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene (2000) 1.33
Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol (1995) 1.29
Redox regulation of p53 during hypoxia. Oncogene (2000) 1.28
Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res (2000) 1.22
Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem (1999) 1.18
Isolation of a cDNA for the catalytic subunit of rat liver glucose-6-phosphatase: regulation of gene expression in FAO hepatoma cells by insulin, dexamethasone and cAMP. Biochem Biophys Res Commun (1994) 1.13
Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5'-flanking sequence. Diabetes (1996) 1.12
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene (1999) 1.12
Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol (2000) 1.12
The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene (2000) 1.09
Regulation of endothelial nitric-oxide synthase during hypoxia. J Biol Chem (1996) 1.08
Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem (1999) 1.06
Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol (2000) 1.06
Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res (2000) 1.04
Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J (2000) 1.01
Multiple epithelial cell-derived factors enhance neutrophil survival. Regulation by glucocorticoids and tumor necrosis factor-alpha. Am J Respir Cell Mol Biol (1999) 0.97
Predominant localization of phosphoenolpyruvate carboxykinase mRNA in the periportal zone of rat liver parenchyma demonstrated by in situ hybridization. FEBS Lett (1989) 0.97
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene (2000) 0.96
Dexamethasone induced proliferation of cultured retinal pigment epithelial cells. Curr Eye Res (1994) 0.93
Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res (1999) 0.91
p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem Biophys Res Commun (1999) 0.90
Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res (2000) 0.89
Acute hypoxia upregulates NOS gene expression in rats. Am J Physiol (1997) 0.88
NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. Cell Res (1999) 0.88
Inhibition by dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: a possible association with Bcl-xL induction. Hepatology (1998) 0.88
Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett (1997) 0.87
Involvement of 3',5'-cyclic adenosine monophosphate regulatory element binding protein (CREB) in both basal and hormone-mediated expression of the phosphoenolpyruvate carboxykinase (PEPCK) gene. Mol Endocrinol (1993) 0.85
CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest (1998) 0.85
Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2. Endocrinology (2001) 0.84
Mutagenesis of the glucocorticoid receptor in mice. J Steroid Biochem Mol Biol (1999) 0.83
Mechanism of gluconeogenesis inhibition in rat hepatocytes isolated after in vivo hypoxia. Am J Physiol (1995) 0.80
Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. FASEB J (1999) 0.80
Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1). Oncogene (1999) 0.79
The pro-apoptotic protein death-associated protein 3 (DAP3) interacts with the glucocorticoid receptor and affects the receptor function. Biochem J (2000) 0.78
Hypoxic effects on the expression of mineralocorticoid and glucocorticoid receptors in human renal cortex epithelial cells. Biochem Biophys Res Commun (1996) 0.78
Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. Oncogene (2000) 0.78
Enhanced proliferation of human fibroblasts, in the presence of dexamethasone, is accompanied by changes in p21Waf1/Cip1/Sdi1 and the insulin-like growth factor type 1 receptor. J Cell Physiol (1998) 0.77
Promoter sequences of eukaryotic protein-coding genes. Science (1980) 19.96
The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 15.12
Specific in vitro transcription of conalbumin gene is drastically decreased by single-point mutation in T-A-T-A box homology sequence. Proc Natl Acad Sci U S A (1980) 10.27
Specific in vitro initiation of transcription on conalbumin and ovalbumin genes and comparison with adenovirus-2 early and late genes. Nature (1980) 10.22
The SV40 72 bp repeat preferentially potentiates transcription starting from proximal natural or substitute promoter elements. Cell (1983) 5.67
The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J (1990) 2.73
The immunoglobulin heavy-chain B-lymphocyte enhancer efficiently stimulates transcription in non-lymphoid cells. EMBO J (1986) 2.56
A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum. Nature (1988) 2.48
Stimulation of in vitro transcription from heterologous promoters by the simian virus 40 enhancer. Proc Natl Acad Sci U S A (1984) 2.44
Short and long range activation by the SV40 enhancer. Nucleic Acids Res (1984) 2.35
A T to A base substitution and small deletions in the conalbumin TATA box drastically decrease specific in vitro transcription. Nucleic Acids Res (1981) 2.31
The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J (1991) 2.30
The c-Ha-ras oncogene and a tumor promoter activate the polyoma virus enhancer. Cell (1987) 2.24
Transforming but not immortalizing oncogenes activate the transcription factor PEA1. EMBO J (1988) 2.14
Net, a new ets transcription factor that is activated by Ras. Genes Dev (1994) 2.12
Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev (1996) 1.98
PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes. EMBO J (1989) 1.97
A novel modulator domain of Ets transcription factors. Genes Dev (1992) 1.97
Transformation suppressor activity of a Jun transcription factor lacking its activation domain. Nature (1991) 1.92
Net, a negative Ras-switchable TCF, contains a second inhibition domain, the CID, that mediates repression through interactions with CtBP and de-acetylation. EMBO J (1999) 1.76
Negative regulation contributes to tissue specificity of the immunoglobulin heavy-chain enhancer. Mol Cell Biol (1987) 1.71
Expression of raf oncogenes activates the PEA1 transcription factor motif. Mol Cell Biol (1989) 1.66
Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene (2008) 1.63
Nuclear targets for transcription regulation by oncogenes. Trends Genet (1991) 1.60
The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene (2001) 1.57
Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene (2006) 1.56
Point mutation in the TATA box curtails expression of sea urchin H2A histone gene in vivo. Nature (1981) 1.51
Effect of histone acetylation on structure and in vitro transcription of chromatin. Nucleic Acids Res (1978) 1.43
Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene (1997) 1.41
Preferential in vitro assembly of nucleosome cores on some AT-rich regions of SV40 DNA. Nucleic Acids Res (1979) 1.41
The immunoglobulin heavy chain enhancer is stimulated by the adenovirus type 2 E1A products in mouse fibroblasts. Proc Natl Acad Sci U S A (1986) 1.39
ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines. Br J Cancer (2010) 1.38
Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J (1996) 1.34
Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins. Proc Natl Acad Sci U S A (1993) 1.29
Mutational analysis of the contribution of sequence motifs within the IgH enhancer to tissue specific transcriptional activation. Nucleic Acids Res (1988) 1.26
Two independent activation domains in c-Ets-1 and c-Ets-2 located in non-conserved sequences of the ets gene family. Oncogene (1992) 1.25
Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer (2003) 1.23
Net (ERP/SAP2) one of the Ras-inducible TCFs, has a novel inhibitory domain with resemblance to the helix-loop-helix motif. EMBO J (1996) 1.22
Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. EMBO J (2001) 1.20
Reversion of Ras transformed cells by Ets transdominant mutants. Oncogene (1994) 1.14
Transcription by eukaryotic RNA polymerases A and B of chromatin assembled in vitro. Eur J Biochem (1979) 1.12
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene (1999) 1.12
Transcription of in vitro assembled chromatin by Escherichia coli RNA polymerase. J Mol Biol (1979) 1.12
v-jun is a transcriptional activator, but not in all cell-lines. Nucleic Acids Res (1988) 1.12
The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem (1997) 1.11
The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene (2000) 1.09
MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene (1995) 1.08
Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Med (1997) 1.08
Cell-specific regulation of oncogene-responsive sequences of the c-fos promoter. Mol Cell Biol (1991) 1.07
The net repressor is regulated by nuclear export in response to anisomycin, UV, and heat shock. Mol Cell Biol (1999) 1.06
MDM2 expression during mouse embryogenesis and the requirement of p53. Mech Dev (1998) 1.04
Net, an Ets ternary complex transcription factor, is expressed in sites of vasculogenesis, angiogenesis, and chondrogenesis during mouse development. Mech Dev (2001) 1.04
Functional interaction of c-Ets-1 and GHF-1/Pit-1 mediates Ras activation of pituitary-specific gene expression: mapping of the essential c-Ets-1 domain. Mol Cell Biol (1995) 1.04
B-lymphocyte targeting of gene expression in transgenic mice with the immunoglobulin heavy-chain enhancer. Nucleic Acids Res (1986) 1.01
MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. Oncogene (1999) 1.01
Interaction of Ets-1 and the POU-homeodomain protein GHF-1/Pit-1 reconstitutes pituitary-specific gene expression. Mol Cell Biol (1997) 1.01
Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J (2000) 1.01
MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J (2000) 1.01
Oncogene v-jun modulates DNA replication. Oncogene (1990) 1.01
The ternary complex factor Net contains two distinct elements that mediate different responses to MAP kinase signalling cascades. Oncogene (2000) 0.99
Studies on the mechanism of transcription of nucleosomal complexes. Eur J Biochem (1980) 0.99
AP1, a composite transcription factor implicated in abnormal growth control. Prog Growth Factor Res (1989) 0.98
The MLV and SV40 enhancers have a similar pattern of transcriptional activation. Nucleic Acids Res (1984) 0.95
The ternary complex factor Net/Elk-3 participates in the transcriptional response to hypoxia and regulates HIF-1 alpha. Oncogene (2007) 0.93
Potentiator effect of the SV40 72-bp repeat on initiation of transcription from heterologous promoter elements. Cold Spring Harb Symp Quant Biol (1983) 0.92
Oncogenic conversion of Ets affects redox regulation in-vivo and in-vitro. Nucleic Acids Res (1993) 0.91
Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. Nucleic Acids Res (1992) 0.90
The oncoprotein v-Ets is less selective in DNA binding than c-Ets-1 due to the C-terminal sequence change. Oncogene (1994) 0.89
Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53. J Mol Recognit (2000) 0.89
Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme. Oncogene (1997) 0.86
Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer Res (2000) 0.86
Locations of the ets subfamily members net, elk1, and sap1 (ELK3, ELK1, and ELK4) on three homologous regions of the mouse and human genomes. Genomics (1995) 0.86
Net-b, a Ras-insensitive factor that forms ternary complexes with serum response factor on the serum response element of the fos promoter. Mol Cell Biol (1997) 0.85
Oncogenic conversion alters the transcriptional properties of ets. Cell Growth Differ (1992) 0.84
Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol (2001) 0.83
Tumorigenic and metastatic properties of two ras-oncogene transfected rat fibrosarcoma cell lines defective in c-jun. Oncogene (1994) 0.83
The apoptotic and transcriptional transactivation activities of p53 can be dissociated. Biochem Cell Biol (1997) 0.82
Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res (1998) 0.81
Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma. Br J Cancer (2004) 0.80
Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells. Mol Cell Biol (2000) 0.80
Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. Br J Cancer (2006) 0.80
Cloning and characterization of GETS-1, a goldfish Ets family member that functions as a transcriptional repressor in muscle. Biochem J (1998) 0.80
Correlation between p53 gene mutations and circulating antibodies in betel- and tobacco-consuming North Indian population. Oral Oncol (2001) 0.79
The activation of RNA polymerase by alkylammonium ions. Nucleic Acids Res (1975) 0.79
Repression by Jun of the Polyoma-virus enhancer overrides activation in a cell specific manner. Nucleic Acids Res (1991) 0.78
Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. Oncogene (2000) 0.78
Ets transcription factor binding site is required for positive and TNF alpha-induced negative promoter regulation. Nucleic Acids Res (1993) 0.78
Chemical modification of ribonucleic acid polymerase with N-bromosuccinimide. Biochem Soc Trans (1975) 0.77
A novel eukaryotic promoter element: the simian virus 40 72 base pair repeat. Fed Proc (1984) 0.77
The isolation, mapping and transcription in vitro of a beta 0-thalassaemia globin gene. Eur J Biochem (1981) 0.76
The conalbumin "TATA" box sequence and the SV40 72 base-pair repeat region influence expression of a chimeric gene in vivo. Prog Clin Biol Res (1982) 0.75